Atrial Fibrillation

Atrial fibrillation portfolio

Between May and August 2016 we have reviewed our portfolio of reviews on atrial fibrillation (progress update in orange, June 2017). We are grateful for the advice we received from Ami Banerjee, Carlos Morillo and Guy Amit. 

We have identified three priority reviews: 

We further identified a number of reviews in need of an update and are currently in contact with the authors: 

  • Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation - update in progress
  • Electrical cardioversion for atrial fibrillation and flutter and Pharmacological cardioversion for atrial fibrillation and flutter - merged and started as new protocol with a new author team
  • Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery

Two reviews is currently being done

Two reviews are currently being updated

One review has recently been published and the need for updating will be reviewed when new evidence becomes available

Two potentially new topics have also been identified but they need further investigation whether or not a review is warranted: 

  • Cognitive behaviour therapy for patients with atrial fibrillation
  • Left atrial appendage closure for prevention of stroke

A number of previously registered review titles are now considered not relevant and will therefore not be pursued further: 

  • Surgical ablation for atrial fibrillation
  • Digoxin for cardioversion in patients with atrial fibrillation
  • Perioperative intravenous magnesium for preventing atrial fibrillation following coronary artery bypass
  • Pharmacological interventions for atrial fibrillation
  • Rhythm control versus rate control for atrial fibrillation/flutter
  • The use of antiarrhythmics prior to cardioversion or catheter ablation for atrial fibrillation
  • Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter